Grifols appoints Tomás Dagá as Vice President of the board of Grifols Egypt (GEPD) and accelerates plasma self-sufficiency for 2026

- ***The appointment will help drive industrial consolidation, regulatory compliance and the strategic relationship with the Egyptian authorities, with whom the company reached an agreement in 2020***

- ***With a joint investment close to 280 million euros, Grifols is working to achieve plasma self-sufficiency in the country before 2026***

- ***Grifols has already created 1,200 high-quality direct jobs with advanced technical training and more than 14,000 indirect jobs in Egypt***

Barcelona, November 27, 2025 - Grifols, S.A. (MCE: GRF, NASDAQ: GRFS), a global leader in plasma-derived medicines and innovative healthcare solutions, today announced the appointment of Tomás Dagá, Grifols' board member, as Vice President of the board of Grifols Egypt for Plasma Derivatives (GEPD), the joint venture created together with the Government of Egypt to deploy the country's first comprehensive plasma ecosystem, and the first in Africa and the Middle East. With this appointment, Grifols strengthens the alliance and strategic direction of a key project for Egypt's healthcare self-sufficiency and for the company's leadership in the global plasma industry.

The company continues working to consolidate in Egypt the entire value chain for the manufacturing of medicines derived from locally sourced plasma, and to guarantee their long-term supply to the entire Egyptian population. Currently, Grifols has 16 donation centers in Egypt, with four additional centers to be added during 2026, as well as an analysis laboratory and a comprehensive plasma logistics center that ensures full traceability and maximum control throughout the entire value chain, as has been the case in all Grifols operations since 1971. Additionally, Grifols is finalizing the construction of a plasma processing plant in Egypt, the first phase of which will be operational in 2026. The donation centers have passed the PPTA and European authorities' inspections to ensure compliance with the highest safety and quality standards in their processes.

After leading the strategy of this project, which began in 2020, Dagá—also a member of Grifols' Strategy Committee, responsible for the company's long-term vision—will now take on the responsibility of driving the project's industrial and regulatory consolidation, strengthening institutional relations with the Egyptian authorities, and accelerating the full operational launch of the entire value chain.

Tomás Dagá, Grifols' board member and Vice President of GEPD, said: "GEPD is a transformative project for Egypt and for the future of the plasma industry. Grifols aims to make the country a global reference point and a spearhead for healthcare self-sufficiency policies, an example of how a nation can treat its own patients and revolutionize healthcare coverage, redefining biomedical capabilities through knowledge transfer, specialized technical training, and the creation of skilled employment." He added: "As Vice President of GEPD, I will work to consolidate the project's economic, healthcare, and social impact in the country and to position Egypt as a leader in advancing the project's international rollout."

Anne-Catherine Berner, Chairwoman of Grifols and of the Strategy Committee, said: "Tomás Dagá is a key leader for Grifols, bringing more than thirty years of experience, deep business knowledge and a long-term vision to advance with greater ambition in a market that is so strategic for the company. His appointment ensures the consolidation of the project in Egypt and its projection on a global scale."

The appointment falls within the work of the Strategy Committee of the Board of Directors, recently created to ensure that the company's growth is aligned with Grifols' long-term vision and with a robust and demanding model.

Grifols shapes the future of the global plasma industry from Egypt

Achieving self-sufficiency in plasma-derived medicines is a technical, economic, and logistical challenge that few countries have managed to overcome. Without a network of donation centers, processing infrastructure, and an enabling regulatory framework, dependency on external supplies becomes unavoidable. This was the case in Egypt, where, according to United Nations data, reliance on third parties posed a tangible risk for the healthcare system of a nation with more than 115 million inhabitants.

In 2020, the Egyptian Government and Grifols sealed a strategic partnership that today stands as an international benchmark. As a result, Grifols Egypt for Plasma Derivatives (GEPD) was created—a public-private collaboration built from scratch that enables the country to produce its own plasma-derived medicines.

The alliance required adapting Egypt's regulatory framework to the international plasma-derived medicines model, in a process carried out jointly with the Egyptian Drug Authority (EDA). For the first time, the EDA has certified a specific regulation governing the collection and processing of plasma in the country under leading international standards. This qualitative leap has enabled the construction of an integrated "Grifols-grade" chain that embeds best-in-class safety protocols and full plasma traceability.

Since its launch in 2020, GEPD has evolved from an ambitious public-private vision into one of the world's most transformative healthcare industrial projects. Five years on, it has already established the foundations of a national industry built on healthcare sovereignty, knowledge transfer, and sustainable development.

A transformative industrial model with major economic, clinical, and social impact

With a joint investment close to €280 million, the project has enabled Egypt to transition from dependency on imported plasma-derived products to consolidating its own industrial model, one with the potential to become a regional reference in biomedical production and a case study on how public-private cooperation can reshape a health system from within.

The project's industrial scale has delivered significant economic impact: Grifols, through GEPD, has created 1,200 high-quality, technically skilled direct jobs, approximately 10,150 indirect jobs and 4,200 induced jobs across the country. It is also catalyzing the growth of a new network of local suppliers, generating a multiplier effect across the national economy.

In parallel, the project is redefining Egypt's biomedical capabilities through knowledge transfer, specialized technical training and qualified job creation. The company has established the Grifols Academy for Plasmapheresis, the first African institution dedicated to technical training in this field, where more than 170,000 hours of instruction have already been delivered. This academy is the backbone of the initiative, ensuring that Egyptian professionals can operate the model independently and sustainably.

The Grifols model, designed to meet the country's current needs and lay the foundations for long-term health, economic and social impact, is poised to position Egypt as a regional hub. Its strategic location between Africa and the Middle East, combined with its new industrial ecosystem, opens the door to becoming a regional supplier of plasma-derived medicines and a replicable model for other nations aiming to reduce reliance on imported plasma.

Plasma self-sufficiency, one of Grifols' strategic pillars

The company drives projects that enable countries to achieve self-sufficiency, meaning the ability to produce and supply their citizens with their own plasma-derived medicines, eliminating reliance on foreign plasma and strengthening the resilience of their health systems. Backed by more than 116 years of experience, Grifols manages around 30 percent of the world's plasma and operates a network of more than 400 donation centers. Its vertically integrated model, from donation to the final medicine, ensures traceability, quality, and healthcare sovereignty, making it a reference for patients, health systems, and governments worldwide.

Through public-private partnerships, such as those developed in Canada with Canadian Blood Services (CBS) or with the Government of Egypt, Grifols contributes to building sustainable national plasma collection and production networks that reinforce strategic autonomy, supply security, and equitable access to essential therapies.

In a context of rising global demand for immunoglobulins and albumin, coupled with vulnerabilities in international supply chains, the company reaffirms its commitment to self-sufficiency as a driver of health, economic development and industrial sovereignty, and stands as the only pharmaceutical company with the real capability to guarantee plasma self-sufficiency.

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life- threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life.

Grifols is focused on treating conditions across four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with close to 400 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,800 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership. The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the IBEX-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com

MEDIA CONTACTS:
Aida Prados
aprados@estudiodecomunicacion.com
Tel. +34 91 576 52 50

LEGAL DISCLAIMER

the manufacture of its products, the appearance on the market of competing products, or changes in the regulatory framework of the markets in which it operates, among others. At the date of preparation of this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. assumes no obligation to publicly report, revise or update the projections or future hypotheses to adapt them to facts or circumstances after the date of writing of this report, except when expressly required by applicable legislation. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Law 6/2023, of 17 March, on the Securities Markets and Investment Services, and any regulations implementing said legislation. Furthermore, this document does not constitute an offer to purchase, sell or exchange, or a solicitation of an offer to purchase, sell or exchange any securities, or a solicitation of any vote or approval in any other jurisdiction. The information contained in this document has not been verified or revised by the external auditors of the Grifols group.